Parse Biosciences is a technology company.
Parse Biosciences has raised $49.0M across 2 funding rounds.
Parse Biosciences has raised $49.0M in total across 2 funding rounds.
Parse Biosciences is a Seattle-based biotechnology company founded in 2018 that develops scalable single-cell sequencing platforms for researchers.[1][2][6] Its core product, the Evercode™ technology, uses combinatorial barcoding to enable high-throughput single-cell RNA sequencing without specialized instruments, serving academic labs, biotech firms, and pharmaceutical researchers studying complex biology like cancer, immunotherapy, and stem cell therapy.[2][4] This solves key pain points in traditional microfluidics-based methods, such as limited scale, high costs, and equipment dependency, allowing unprecedented experiment sizes—over 3,000 labs worldwide have processed millions of cells with it.[1][4] The company has shown strong growth momentum, evolving from SPLiT Biosciences and driving innovations in areas like developmental biology and neurology.[2][6]
Parse Biosciences emerged from groundbreaking academic research in single-cell sequencing. The technology stems from SPLiT-seq, a split-pool combinatorial barcoding method published in *Science* in 2018, which inspired the company's founding that same year at the University of Washington ecosystem via CoMotion.[1][6] Originally named SPLiT Biosciences, it rebranded to Parse Biosciences to reflect its focus on scalable tools.[6] Founders drew from expertise in genomics and biotech, aiming to democratize single-cell analysis amid rising demand for insights into diseases like COVID-19 and cancer.[2] Early traction came from proving the tech's ability to handle massive cell counts without custom hardware, quickly attracting researchers and fueling rapid innovation.[1][4]
Parse stands out in single-cell sequencing through these key advantages:
Parse rides the explosive growth of single-cell genomics, a trend transforming biology by revealing cellular heterogeneity critical for precision medicine, drug discovery, and understanding diseases like cancer and neurodegeneration.[1][2] Timing is ideal: post-2018 SPLiT-seq publication aligned with surging demand from COVID-19 research and advances in immunotherapy, where single-cell data unlocks hidden biology.[2] Market tailwinds include falling sequencing costs, AI-driven analysis, and biotech's push for scalable tools—Parse influences the ecosystem by lowering barriers, enabling smaller labs to compete, and fostering breakthroughs in stem cell therapy and vascular disease.[2][4] As a private player (no IPO yet), it complements giants like 10x Genomics while carving a niche in high-scale, accessible tech.[3][5]
Parse is poised to dominate scalable single-cell sequencing as labs demand ever-larger datasets for AI-powered biology. Next steps likely include expanding Evercode kits, deeper software integrations, and potential funding or IPO amid biotech's recovery—watch for partnerships in drug development.[3][4][5] Trends like multi-omics and fixed-sample workflows will propel it, evolving its role from enabler to ecosystem leader in human health discoveries. This Seattle innovator, born from SPLiT-seq's spark, continues scaling science without limits.[1][2]
Parse Biosciences has raised $49.0M in total across 2 funding rounds.
Parse Biosciences's investors include Bioeconomy Capital.
Parse Biosciences has raised $49.0M across 2 funding rounds. Most recently, it raised $42.0M Series B in February 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2022 | $42.0M Series B | Bioeconomy Capital | |
| Jan 1, 2021 | $7.0M Series A | Bioeconomy Capital |